16-03-2010 15:02 3/16/2010-Shares of Icagen (NASDAQ:ICGN) are trading 40.5% higher to $0.76 Tuesday after the company reported positive results in its Phase IIa epilepsy study of ICA-105665, its novel orally available small molecule KCNQ potassium channel agonist. "The trial met its endpoints," noted Jacqueline A. French, MD, Professor and Director of the Clinical Trials Consortium at the NYU Comprehensive Epilepsy Center, "While more studies will be required to establish the potential utility of this compound in the treatment of epilepsy, the results of this photosensitive epilepsy model provide important proof-of-concept data for this novel drug candidate."
Read the original here:
News Update: Icagen Soars on Positive Study Results for ICA-105665 Epilepsy Treatment Compound - Video